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Preliminary results from the DIRECT-II Study: a prospective, randomized,
active-control, multi-center, non-inferiority study comparing the safety and
efﬁcacy of the Svelte drug-eluting coronary stent IDS to the Medtronic Vascular
(Santa Rosa, CA) Resolute IntegrityTM DES
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Background: The Svelte (New Providence, NJ) drug-eluting stent (DES) combines
sirolimus with a novel, amino acid-based (PEA) bioabsorbable drug carrier. The stent
is mounted on an Integrated Delivery System (IDS) consisting of a low compliant
balloon with balloon control bands (BCBs) enveloping the balloon edges and afﬁxed
to a 0.014" wire, providing an ultra low proﬁle, highly ﬂexible drug-eluting coronary
stent system speciﬁcally designed for direct stenting. The DIRECT I First-In-Man
study (Webster, Ormiston et al., n¼30) reported 0% clinically-driven MACE at
12-months with 2.7% stent volume obstruction (via IVUS) and 98% strut coverage
(via OCT) observed at 6-months. All imaging was reviewed and adjudicated by
independent core lab and DSMB
Methods: The DIRECT II study is a prospective, randomized, active-control, multi-
center, non-inferiority study comparing the safety and efﬁcacy of the Svelte drug-
eluting coronary stent IDS to the Medtronic Vascular (Santa Rosa, CA) Resolute
IntegrityTM DES. 159 patients (2:1 randomization Svelte IDS : Resolute IntegrityTM)
were treated with angiographic follow-up scheduled at 6-months to assess the primary
endpoints of TVF and LL. Patients with symptomatic ischemic heart disease due to de
novo stenotic lesions in arteries with RVD 2.5mm – 3.5mm and lesion length < 20
mm were included. Stent evaluation post-procedure and at 6-month follow-up in
30 patients was also performed at sites with OCT capability. Additional clinical
follow-up will take place through 5-years for all patients. Enrolment began January
2013 and will complete August 2013.
Results: Procedural and 30-day data on all patients, alongwith OCT image analysis, will
be presented. Comparative data for time and cost savings, including overall procedural
time, adjunctive product use, contrast use and radiation exposure, will be reported.
Conclusions: A review of the Svelte DES platform and available procedural and 30-
day results from the study will be provided. These data provide insights into the
potential procedural and clinical beneﬁts, as well as time and cost savings, of this
unique drug-eluting stent system.
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Background: The Svelte (New Providence, NJ) drug-eluting stent combines sirolimus
with a novel, amino acid-based fully bioabsorbable drug carrier. The stent is mounted
on an Integrated Delivery System (IDS) consisting of a low compliant balloon with
balloon control bands enveloping the balloon edges and afﬁxed to a 0.014" wire,
providing a very low proﬁle, ﬂexible, drug-eluting coronary stent system speciﬁcally
designed for direct stenting. The DIRECT I ﬁrst-in-man study was designed to
evaluate the feasibility of the Svelte drug-eluting stent IDS.
Methods: 30 patients with a de novo lesion in a native coronary artery, with a reference
vessel diameter between 2.5 mm and 3.5 mm and lesion length < 23 mm, were
assessed. Patients with successful, uncomplicated treatment of one additional lesion in
a non-target vessel were also included. All patients completed 6-month QCA and IVUS
(+ OCT in a subset) and are followed clinically for 5-years. The study primary endpoints
were target vessel failure and angiographic late lumen loss at 6-months.
Results: At 6 months, no patient had suffered a clinically-driven MACE, there was
2.7% stent volume obstruction (via IVUS) and stent strut coverage was 98% (via
OCT). There were no adverse clinical results between 6 and 12 months, indicating no
evidence of late catch-up. Full independent core lab and DSMB-adjudicated baseline
and 6 month QCA, IVUS and OCT data, and clinical outcomes to 12-months will be
reported.
Conclusions: The Svelte sirolimus-eluting coronary stent IDS, utilizing an anti-
inﬂammatory, naturally-occurring amino acid-based drug carrier, demonstrated
excellent clinical outcomes, low neointimal proliferation, and uniform vessel healing
at 6-months. The clinical beneﬁt was sustained in all patients through 12-months.
DIRECT II, a prospective, randomized, active-control, multi-center, non-inferiority
study is currently underway.B64 JACC Vol 62/18/Suppl B j October 27–November 1, 2013TCT-198
Six Years Consecutive Complete Follow-up Result of Sirolimus Eluting Stent
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Background: In many reports, SES is more effective in decreasing late lumen loss
and restenosis rate than BMS. However, long-term follow-up results of SES remain
unclear. We sometimes experience late restenosis cases in SES implanted lesion.
Methods: We tried angiographic follow-up every year of the patients SES implanted.
We could follow 60 lesions completely and evaluated MLD of those lesions in each
year. We ruled out revascularised lesions. We sometimes experience late restenosis
cases in SES implanted lesion.
Results: We implanted SES in 3972 lesions in the heart center from April 2004 to
August 2012. We studied consecutive 58 lesions we could follow up every year. We
estimated the changes of MLD of these 58 lesions. During 1 to 2-year follow-up, there
is not remarkable change in MLD (1-year: 2.620.55, 2-year: 2.490.56). But at
3-year follow-up, MLD got smaller remarkably (3-year:2.290.65). After that there is
not remarkable change (4-year: 2.300.70, 5-year:2.260.74, 6-year:2.210.58).
7.4% of 3-year follow-up patients, 5.5% of 4-year follow-up patients and 7.5% of
5-year follow-up patients are ruled out by revascularization.Conclusions: MLD of SES implanted lesions get smaller. The extent of lumen loss
was large after 3 years of PCI. We have to follow up SES implanted patients carefully
and continuously because of late stent thrombosis and late restenosis. But this result
suggest that late restenosis becomes less common in 4 years or later after SES
implanted.TCT-199
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Background: A novel sirolimus-eluting stent with a bioabsorbable polymer (Osiro,
Biotronik, Germany) is now available. The safety and efﬁcacy of this drug-eluting
stent (DES) in an all comers setting is unknown.
Methods: Between June 2011 and January 2013, 234 patients were treated with the
Osiro (Biotronik, Germany) stent. Indication for the Osiro (Biotronik, Germany) was
left to the operator discretion. Demographic, clinical and procedural characteristics
were collected through institutional and catheterization databases review. Short and
long-term clinical follow-up were available through institutional database review and
telephone contact.
Results: The mean age was 6510 years with a predominance of male (76%). They
had hypertension in 70% and diabetes in 35% of cases. Coronary artery disease was
already known in most patients as 47% had a previous percutaneous coronary
intervention 40% had a myocardial infarction (MI) and 18% had previous coronary
artery bypass surgery. Clinical presentation was acute coronary syndrome in 77% of
patients. Mean reference diameter was 2.80.5mm, lesion length was 2215 mm
and lesion stenosis was 8013%. The mean used stent diameter and length were
2.80.4mm and 226mm respectively. Osiro stent was used to treat bifurcation
lesion in 34% and thrombus-containing lesion in 11%. Procedural and technicalj TCT Abstracts/POSTER/Bare Metal and Drug-Eluting Stent Studies
www.jacctctabstracts2013.com TUESDAY, OCTOBER 29, 2013, 3:30 PM–5:30 PMsuccesses were achieved in 95% of cases. Type B2/C lesions were treated in 63% of
cases. Long-term follow-up showed a combined major adverse cardiac events rate
(death, MI and target lesion revascularization (TLR)) of 11%. All cause mortality
was noted in 5%, cardiac mortality in 1%, MI in 6% and stroke in 1%. Finally, TLR
and target vessel revascularization were noted in 3% and 4% of cases respectively.
The independent predictors of MACE were cancer (Odds Ratio (OR): 6.55 [2.64,
16.28]; p<0.001), respiratory disease (OR: 4.41 [1.68, 10.47]; p<0.001), post-
dilation (OR: 2.85 [1.19-6.80]; p¼ 0.018) and type C lesions (OR: 1.91 [1.02-3.56];
p¼ 0.042).
Conclusions: In this real life cohort, the treatment of highly complex lesions with the
Osiro Stent was associated with excellent long-term results. Further randomized trials
are warranted to conﬁrm these ﬁndings.TCT-200
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Background: Long term safety and efﬁcacy of the Elixir DESyne BD Novolimus
Eluting Coronary Stent System (NECSS), a Co-Cr stent with a bioabsorbable polymer
compared to the control Endeavor Zotarolimus Eluting Coronary Stent System is not
known
Methods: 149 patients were randomized 3:1, either to the Elixir DESyne BD
Novolimus Eluting CSS loaded with 5mcg per mm of stent length of Novolimus,
a sirolimus metabolite, eluted via a bioabsorbable polylactide-based polymer, or to
the Endeavor Zotarolimus-eluting CSS (ZECSS) loaded with 10mcg per mm of
stent length of Zotarolimus eluted via a durable phosphoryl choline polymer. All
patients were analyzed for the primary endpoint of in-stent late lumen loss (LLL)
assessed by qualitative coronary angiography (QCA) at 6 months. Moreover, all
patients underwent evaluation for the secondary endpoints including the Device-
orientated Composite Endpoint (DoCE) deﬁned as: cardiac death, MI not clearly
attributable to a non-intervention vessel, and clinically-indicated target lesion
revascularization; clinically-indicated Target Vessel Revascularization (TVR), and
stent thrombosis at 1, 6, 9, and 12 months and annually through 5 years. Lesions
were also evaluated for angiographic endpoints at 6 months including: in-segment
LLL, percent diameter stenosis, minimal lumen diameter post-procedure, and
angiographic binary restenosis (ABR) (50%). A subset of patients underwent
intravascular ultrasound (IVUS) evaluation including percent (%) neointimal
obstruction at 6 months.
Results: The study met the primary endpoint demonstrating both non-inferiority and
superiority of the DESyne BD compared to the control (0.120.15 vs 0.670.47,
p<0.001), additionally, in-stent ABR was signiﬁcantly lower for DESyne BD (0% vs
7.9%, p¼0.003). Excellent clinical results at 6 months were demonstrated for both
devices (DoCE 2.7% vs. 3.2%, p¼ 1.00). Sustained low clinical event rates were
observed at 12 months and 24 months (DoCE 2.7% vs 3.2% p¼1.0)
Conclusions: The DESyne BD NECSS demonstrated sequential non-inferiority and
superiority over a durable polymer Endeavor ZECSS for in-stent late lumen loss at 6
months. Clinical events remained low through 24 months suggesting long term
safety.P
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The middle-term outcome of small-vessel stenting with the second-generation
drug-eluting stents.
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Background: The outcome of small-vessel stenting with the second-generation drug-
eluting stents (DES) remains uncertain. Stents deployed in small arteries, have
a higher metal-to-artery ratio; this may increase the risk of restenosis. Speciﬁc attri-
butes of stent design, including strut thickness and eluting drug, inﬂuence stent
performance characteristics, particularly in smaller coronary vessels.
Methods: This study is a single-center, retrospective observational study. From April
2009 to December 2011, 264 patients with small vessel coronary artery disease wereJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstrtreated with 2.5mm DES implantation, which consisted of 225 patients with 2.5mm
Everolimus eluting stent (EES) implantation and 39 patients with 2.5mm Biolimus
eluting stent (BES) implantation. Out of these patients, 226 patients underwent follow-
up coronary angiography at eight months post-PCI. We evaluated the results of those
226 patients.
Results: Though pre-PCI reference vessel diameter were less in EES group than BES
group (EES:2.110.34, BES:2.250.28 mm, p<0.05), there were no signiﬁcant
difference in patient characteristics, pre-PCI minimal lumen diameter(MLD)
(0.690.36, 0.710.41 mm) and angiographic percent diameter sten-
osis(PDS)(67.817.1, 69.318.7 %). Post-PCI MLD of BES group were smaller than
those of EES group. (1.960.31, 2.080.31 mm p<0.05) Post-PCI PDS(11.010.9,
8.310.5 %) and acute gain(1.310.46, 1.440.47 mm) were similar in both groups.
At follow-up coronary angiography eight months later, there were no signiﬁcant
difference in MLD(1.850.55, 2.020.59 mm), PDS(21.620.7, 19.417.1 %),
binary restenosis (17 cases; 7.6%, 3 cases; 7.7%) and target lesion revacularization
(7 cases; 3%, 0 case; 0%).
Conclusions: Though pre-PCI lesion characteristics of BES group were a little better
than those of EES group, there were no signiﬁcant difference between EES and BES
in the middle-term outcome of small-vessel stenting.TCT-202
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Background: Pioglitazone is widely used for glycemic control in patients with type-2
diabetes mellitus (DM), and is associated with a lower risk of cardiovascular events
according to a meta-analysis of randomized trials. To evaluate the effect of pioglita-
zone on ischemic cardiovascular events in Japanese patients with DM and coronary
artery disease, after drug-eluting stents (DESs) implantation, the 12-month data from
the Japan-Drug Eluting Stents Evaluation; a Randomized Trial (J-DESsERT) was
analyzed.
Methods: In this prospective, multicenter trial, 3,533 patients were randomized 1:1
to undergo coronary stenting with Sirolimus-eluting stents or Paclitaxel-eluting
stents. Lesion lengths were 46 mm, with vessel diameters from 2.5 mm to 3.75
mm. Randomization was stratiﬁed based on the presence or absence of DM.
Deﬁnitions for allocation into the DM group at the time of this trial were: 1.
Previous DM diagnosis; 2. Currently on diabetic medication (oral hypoglycemic
drugs or insulin injections); 3. HbA1c (Japan diabetes society [JDS])  6.5% within
30 days before the procedure. Patients who met one or more of the above criteria
were allocated to the DM group. A total of 1,705 patients (48%) with DM were
analyzed from the J-DESsERT trial.
Results: Target vessel revascularization (TVR) is deﬁned as any ischemia-driven
repeat percutaneous coronary intervention (PCI), target vessel bypass surgery, all
death, myocardial infarction (Q wave and non-Q wave), and cerebrovascular
accident (stroke, transient ischemic attack). Including TVR, major adverse cardiac
cerebrovascular events (MACCE) occurred in only 22 of 357 patients (6.33%)
receiving pioglitazone at 12 months. Conversely, substantially more MACCE
events occurred in the group not receiving the pioglitazone, 152 of 1,348 patients
(11.6%, p¼<0.01).
Conclusions: Pioglitazone is associated with a signiﬁcantly lower MACCE rate at
both 8 and 12 months, in Japanese patients with DM, post-DES implantation.TCT-203
Mid-term Follow-Up Results of Drug-eluting Stent Implantations Following
Rotational Atherectomy for Heavily Calciﬁed Lesions: Impact of the Second-
generation Drug-eluting Stent
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Background: The purpose of this study was to evaluate the impact of second-
generation DES (2nd DES) as compared with ﬁrst-generation DES (1st DES) in
patients treated with DES implantation following rotational atherectomy (RA) for
heavily calciﬁed lesions.
Methods: From December 2003 to August 2012, 616 lesions in 492 patients were
treated with 1st DES (Sirolimus-eluting stent [SES] or Paclitaxel-eluting stent [PES])
or 2nd DES (Everolimus-eluting stent [EES] or Biolimus-eluting stent [BES])
implantations following RA exclusively and successfully. Of these lesions, 389
lesions in 312 (63.4%) patients who had undergone 8-month angiographic follow-up
were analysed.acts/POSTER/Bare Metal and Drug-Eluting Stent Studies B65
